quinoxalines has been researched along with Intraocular Pressure in 288 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (0.69) | 18.7374 |
1990's | 48 (16.67) | 18.2507 |
2000's | 156 (54.17) | 29.6817 |
2010's | 74 (25.69) | 24.3611 |
2020's | 8 (2.78) | 2.80 |
Authors | Studies |
---|---|
Ucar, F; Yener, Hİ | 1 |
Inoue, K; Ishida, K; Kunimatsu-Sanuki, S; Tomita, G | 1 |
Del Amo, EM; Ranta, VP; Urtti, A | 1 |
Aihara, M; Kanazawa, M; Kawakita, K; Kojima, S; Nojima, T; Suganami, H; Tanihara, H; Yamamoto, T | 1 |
Bigdeli, A; Feghhi, M; Makhmalzadeh, BS; SoleimaniBiatiani, E | 1 |
Kim, KE; Kim, Y; Lee, CK; Rho, S; Shin, J | 1 |
Aihara, M; Isobe, T; Kanazawa, M; Koizumi, N; Kojima, S; Minami, H; Suganami, H; Tanihara, H; Yamamoto, T | 1 |
Kurysheva, NI | 2 |
Aiello, F; Bagetta, G; Cesareo, M; Corasaniti, MT; Nucci, C; Scuteri, D; Tonin, P | 1 |
Goode, SM; McMenemy, MG; Nguyen, QH; Realini, T; Whitson, JT | 1 |
Balbaba, M; Çelebi, S; Ulaş, F | 1 |
Feke, GT; Pasquale, LR; Rhee, DJ; Turalba, AV | 1 |
Giannopoulos, T; Haidich, AB; Holló, G; Konidaris, V; Konstas, AG; Mikropoulos, DG; Paschalinou, E; Samples, JR; Voudouragkaki, IC | 1 |
Dubiner, H; Katz, G; Sall, K; Samples, J; Vold, S | 1 |
Bonini-Filho, MA; Costa, R; Jorge, R; Katayama, BY; Martin, LF; Messias, AM; Paula, JS | 1 |
Galor, A; Modi, Y; Shah, AA; Thomas, B; Wellik, SR | 1 |
DuBiner, H; Katz, G; Nguyen, QH; Realini, T | 1 |
Baser, EF; Gülhan, C; Öztürk, B; Seymenoğlu, G | 1 |
Cabarga, C; Casado, A; de la Fuente, MA; Muñoz-Negrete, FJ | 1 |
Akat, PB; Jain, SS; Joshi, SR; Karande, VB; Ramanand, JB; Ramanand, SJ | 1 |
De Moraes, CG; Furlanetto, RL; Gardiner, SK; Greenfield, DS; Krupin, T; Liebmann, JM; Ritch, R; Teng, CC | 1 |
Cherukury, M; Durairaj, C; Shen, J | 1 |
Bex, PJ; Chen, TC; Feke, GT; Pasquale, LR; Rhee, DJ; Taylor, CP; Turalba, AV; Wand, M | 1 |
Chi, W; Li, A; Wang, S; Zhu, X | 1 |
Conner, IP; Fedorchak, MV; Little, SR; Medina, CA; Schuman, JS; Wingard, JB | 1 |
Aung, T; Branch, JD; Goldberg, I; Hernandez Paredes, TJ; Laganovska, G; Tsorbatzoglou, A | 1 |
Chew, SK; Goldberg, I; Skalicky, SE | 1 |
Gandolfi, SA; Hamacher, T; Lim, J; Parra Restrepo, JC; Sanseau, AC | 1 |
Agarwal, P; Agarwal, R; Ismail, NM; Kannan Kutty, M; Kapitonova, MY; Razali, N; Salmah Bakar, N; Smirnov, A | 1 |
García-López, A; Hartleben, C; Jiménez-Román, J; Paczka, JA | 1 |
Anand, G; Gelber, AC; Kochar, B; Shan, SJ; Zinreich, SJ | 1 |
Guzman-Aranguez, A; Loma, P; Perez de Lara, MJ; Pintor, J | 1 |
Batoosingh, AL; Cantor, LB; Liu, CC; Safyan, E | 1 |
Melo, LA; Piassi, MV; Prata, TS | 1 |
Batiste, C; Fudemberg, SJ; Katz, LJ | 1 |
Barbosa, WL; Grigera, DE; Hatanaka, M; Jordao, M; Susanna, R | 1 |
Călugăru, D; Călugăru, M | 3 |
Buchholz, P; Kimmich, F; Thelen, U | 1 |
Jewelewicz, DA; Liebmann, J; Radcliffe, NM; Ritch, R | 1 |
Mint, JO; Poling, TR; Schultz, CL | 1 |
Cai, JP; Cheng, JW; Wei, RL | 1 |
Chartrand, JP; Hollander, DA; Nixon, DR; Piemontesi, RL; Simonyi, S; Yan, DB | 1 |
Cheng, JW; Li, Y; Wei, RL | 1 |
Bournias, TE; Lai, J | 1 |
Aktas, Z; Akyürek, N; Göçün, PU; Gurelik, G; Hasanreisoğlu, B; Onol, M | 1 |
Asouhidou, I; Chatzibalis, T; Karabatakis, V; Natsis, K; Nousios, G; Vlasis, K | 1 |
Gul, M; Imrek, S; Ozdemir, G; Tolun, FI | 1 |
Earl, M; Nguyen, QH | 1 |
Campos, JG; Díaz, F; Moreno, M; Pérez de Vargas, I; Vidal, L; Villena, A | 1 |
Katz, LJ; Razeghinejad, MR; Sawchyn, AK | 1 |
Bolívar, G; Hernández-Verdejo, JL; Teus, MA | 1 |
Montgomery, DM; Rahman, MQ; Ramaesh, K | 1 |
Brinkmann, CK; Katsimpris, JM; Lepidas, J; Livieratou, A; Petropoulos, IK; Theoulakis, PE | 1 |
Calvo-González, C; Fernández-Vidal, A; García-Feijoó, J; García-Sánchez, J; Martínez-de-la-Casa, JM; Méndez-Hernández, C; Sáenz-Francés, F | 1 |
Nowroozzadeh, MH; Razeghinejad, MR | 1 |
Alldredge, B; Gerhardt, G; Halverson, K; Pensyl, D; Qualls, C; Sullivan-Mee, M | 1 |
Liu, JH; Medeiros, FA; Slight, JR; Weinreb, RN | 1 |
Bron, AM; Creuzot-Garcher, CP; Diestelhorst, M; Hermann, MM | 1 |
Clark, AF; Millar, JC; Pang, IH | 1 |
Artunay, O; Bahcecioglu, H; Rasier, R; Sengul, A; Unal, M; Yuzbasioglu, E | 1 |
Kim, CS; Kim, JY; Nam, KY | 1 |
Cho, SW; Choi, CY; Kim, JM; Park, KH | 1 |
Diestelhorst, M; Georgopoulos, G; Hermann, MM; Muether, PS; Papaconstantinou, D | 1 |
Bernstein, P; Caprioli, J; Schiffman, RM; Spaeth, GL | 1 |
Hendrikse, F; Peeters, A; Prins, MH; Schouten, JS; Webers, CA | 1 |
Georgakopoulos, CD; Giannopoulos, K; Makri, OE; Pharmakakis, N; Stasinos, S | 1 |
Gardiner, S; Greenfield, DS; Krupin, T; Liebmann, JM; Ritch, R | 1 |
García-Pérez, JL; González-Gordaliza, C; Muñoz-Negrete, FJ; Puerto-Hernández, B; Rebolleda, G | 1 |
Pinar-Sueiro, S; Rivas, MA; Urcola, H; Vecino, E | 1 |
Liu, JH; Realini, T; Weinreb, RN | 1 |
Kim, CY; Kim, HK; Kim, JM; Kim, MS; Kim, TW; Park, KH | 1 |
Grueb, M; Mielke, J; Rohrbach, JM; Schlote, T | 1 |
Altıntaş, O; Cağlar, Y; Gök, M; Yüksel, N | 1 |
Bhagav, P; Chandran, S; Upadhyay, H | 1 |
Shinde, UA; Singh, KH | 1 |
Barton, K; Gill, NK; Haidich, AB; Konstas, AG; Mikropoulos, DG; Quaranta, L; Riva, I; Yan, DB | 1 |
Aburahma, MH; Mahmoud, AA | 1 |
Grüb, M; Mielke, J; Rohrbach, M; Schlote, T | 1 |
Abrams, L; Cantor, L; Ehrlich, R; Harris, A; Hollander, DA; Rusia, D; Shoja, MM; Shoshani, Y; Siesky, B; Williams, JM | 1 |
Grover, DS; Smith, O | 1 |
Beckers, HJ; Hendrikse, F; Jansonius, NM; Schouten, JS; Severens, JL; van Gestel, A; Webers, CA | 1 |
Bell, G; Farag, E; Kalfas, I; Kovaci, B; Kurz, A; Mascha, EJ; Rockwood, E; Sessler, DI; Wang, L | 1 |
Cottingham, AJ; Hollander, DA; Katz, LJ; Rauchman, SH; Schiffman, RM; Simmons, ST; Williams, JM | 1 |
Congdon, NG; Friedman, DS; Gilbert, D; Goggins, W; Kader, MA; Krishnadas, R; Quigley, HA; Ramakrishnan, R; Tielsch, J | 1 |
Chen, DF; Chen, H; Cho, KS; Guo, W; Luo, G; Pang, IH; Wang, WH; Yang, Q; Yu, D | 1 |
Garhöfer, G; Hommer, A; Popa-Cherecheanu, A; Qiao, C; Resch, H; Schmetterer, L; Sperl, P | 1 |
Alakuş, MF; Işcan, Y; Öner, V; Taş, M; Türkyılmaz, K | 1 |
Dot, C; El Chehab, H; Giraud, JM; Le Corre, A; Ract-Madoux, G; Swalduz, B | 1 |
De Moraes, CG; Gardiner, SK; Greenfield, DS; Krupin, T; Liebmann, JM; Ritch, R | 1 |
Cho, HK; Kee, C | 1 |
Chang, TH; Chen, FA; Chien, ST; Horng, CT; Kao, WT; Tsai, MK; Tsai, ML | 1 |
Inoue, Y; Kaneko, E; Minagawa, Y; Wada, T | 1 |
Méndez-Hernández, C | 1 |
Araie, M; Kuwayama, Y; Sugiyama, K; Tanihara, H; Yamazaki, Y | 1 |
Budengeri, P; Cai, JP; Cheng, JW; Wei, RL | 1 |
Baudouin, C; Titouamane, S | 1 |
Bunce, C; Garway-Heath, DF; Hitchings, RA; Indar, A; Poinoosawmy, D | 1 |
Cheng, CY; Chou, JC; Hsu, WM; Ko, YC; Liu, CJ; Liu, JH | 1 |
Ciancaglini, M; Costagliola, C; D'Oronzo, E; Mastropasqua, L; Parmeggiani, F; Sebastiani, A | 1 |
Arrico, L; Di Staso, S; Giuffrè, I; Recupero, SM; Taverniti, L | 1 |
Bottoli, A; Fogagnolo, P; Fumagalli, E; Invernizzi, T; Orzalesi, N; Rossetti, I | 1 |
Gelatt, KN; MacKay, EO | 1 |
Cheng, CY; Chiu, AW; Chou, JC; Hsu, WM; Ko, YC; Liu, CJ; Liu, JH | 1 |
Ermis, SS; Inan, UU; Ozturk, F | 1 |
Matthews, TD; Mushtaq, B; Sardar, J | 1 |
Camras, CB | 2 |
Bojić, L; Mandić, Z; Novak-Laus, K; Sarić, D | 1 |
Kankuri, E; Kotikoski, H; Vapaatalo, H | 1 |
Ge, J; Li, Y; Yu, M | 1 |
Boyle, DR; Cassel, DA; DeLucca, PT; Fletcher, CA; Greff, LJ; Johnson-Pratt, LR; Kolodny, AH; Polis, AB; Sall, KN; Skobieranda, F | 1 |
Batoosingh, A; Felix, C; Mundorf, T; Whitcup, S; Williams, R | 1 |
Faulkner, W | 1 |
Koren, G; Levin, AV; Mungan, NK; Nischal, KK; Wilson, TW | 1 |
Bottoli, A; Fogagnolo, P; Fumagalli, E; Orzalesi, N; Rossetti, L | 1 |
Hommer, A; Kapik, B; Shams, N | 1 |
Ermis, SS; Inan, UU; Oztürk, F; Yücel, A | 1 |
Day, D; Sharpe, ED; Stewart, JA; Stewart, WC | 1 |
Abraham, LM; George, R; Muliyil, J; Parikh, R; Paul, P; Thomas, R | 1 |
Mozaffari, E; Reardon, G; Schwartz, GF | 1 |
Goff, MJ; Kerrison, JB | 1 |
Gouveia, SM; Klingmüller, V; Osborne, NN; Pillunat, LE; Schmidt, KG | 1 |
Bartlett, JD; Evans, DW; Gherghel, D; Hosking, SL | 1 |
Georgiadis, N; Katsimpris, JM; Konstas, AG; Kozobolis, V; Siganos, D | 1 |
Larsson, LI; Tsukamoto, H | 1 |
Harrison, JM; Kiel, JW; McKinnon, SJ; Ransom, NL; Reitsamer, HA | 1 |
Day, DG; Jenkins, JN; Sharpe, ED; Stewart, JA; Stewart, WC | 1 |
Day, DG; Jenkins, J; Stewart, JA; Stewart, WC | 1 |
Day, DG; Henry, CJ; Jenkins, JN; Mundorf, TK; Sharpe, ED; Stewart, JA; Stewart, WC | 1 |
Cassel, DA; DeLucca, PT; Hustad, CM; Kolodny, AH; Skobieranda, F; Solish, AM | 1 |
Fechtner, RD; Henry, C; Hughes, B; Lee, DA; Terry, S; Whitson, JT | 1 |
Arias Puente, A; Carrasco Font, C; García Sáenz, MC; Villarejo Díaz-Maroto, I | 1 |
Cunliffe, I; García-Sánchez, J; Landry, J; Pajic, B; Rouland, JF; Spiegel, D; Traverso, C | 1 |
Beischel, CJ; Day, DG; Rhodes, JS; Sharpe, ED; Stewart, JA; Stewart, WC | 1 |
Becker, HI; Diamant, JI; Walton, RC; Zegans, ME | 1 |
Appaswamy, S; Bhatt, R; Desai, A; Fitt, A; Sandramouli, S; Whittaker, KW | 1 |
Bower, KS; Stutzman, R; Thordsen, JE; Warren, BB | 1 |
Akman, A; Akova, YA; Cetinkaya, A | 1 |
Asagidag, A; Celik, A; Ermis, SS; Inan, UU; Onrat, E; Orman, A; Ozturk, F; Yucel, A | 1 |
Ignat, F | 1 |
Cheng, CY; Hsu, WM; Ko, YC; Liu, CJ | 1 |
Bakri, SJ; Beer, PM | 1 |
Aşagidag, A; Ermiş, SS; Inan, UU; Oztürk, F; Yaman, S | 1 |
Camras, CB; Sheu, WP | 1 |
Gupta, V; Sihota, R; Sony, P | 1 |
Greenfield, DS; Krupin, T; Liebmann, JM; Ritch, R; Rosenberg, LF; Yang, JW | 1 |
Diestelhorst, M; Dinslage, S; Jordan, JF; Krieglstein, GK; Strauss, B | 1 |
Georgiadis, N; Karabatsas, CH; Konstas, AG; Kotsimpou, A; Lallos, N; Stewart, JA; Stewart, WC | 1 |
Cheetham, JK; Chou, C; Craven, ER; Schiffman, R; Walters, TR; Williams, R | 1 |
Kiel, JW; Posey, M; Reitsamer, HA | 1 |
Al-Jadaan, I; Al-Omran, M; Al-Shahwan, S; Al-Torbak, AA; Edward, DP; Turkmani, S | 1 |
Chen, TC | 1 |
Chang, HW; Tsai, JC | 1 |
Susanna, R; Vaidergorn, PG | 1 |
Márquez-de-Aracena, R; Montero-de-Espinosa, I; Morales, C | 1 |
Conkbayir, I; Simsek, T; Yanik, B; Zilelioglu, O | 1 |
Avila, MP; Magacho, L; Queiroz, CF; Reis, R; Santos, LC | 1 |
Aloni, E; Bakalash, S; Ben Simon, GJ; Rosner, M | 1 |
Carassa, R; Gandolfi, S; Manni, G; Marchini, G; Mastropasqua, L; Montanari, P; Orzalesi, N; Quaranta, L; Ratiglia, R; Rossetti, L; Traverso, C; Uva, M | 1 |
Gandolfo, E; Gandolfo, F; Musig, A; Pizzolante, T; Quaranta, L; Rovida, F; Turano, R | 1 |
Hong, YJ; Lee, JH; Seong, GJ; Yeom, HY | 1 |
Jurisić, D; Lacmnovic-Loncar, V; Mandić, Z; Petric, I; Sesar, A; Sesar, I; Tomić, Z | 1 |
Andrew, RM; Bergamini, MV; Bosworth, CF; Dickerson, JE; James, JE; Landry, TA; Moster, MR; Ochsner, KI; Silver, LH; Sullivan, EK; Wells, DT; Whitson, JT | 1 |
Baudouin, C; Bron, AM; Creuzot-Garcher, C; Lizard, G; Malvitte, L; Montange, T; Vejux, A | 1 |
Batoosingh, AL; Chou, C; Craven, ER; DuBiner, HB; Schiffman, RM; Sherwood, MB; Whitcup, SM | 1 |
Fiscella, R | 1 |
Goñi, FJ | 1 |
Greenfield, DS; Krupin, T; Liebmann, JM; Ritch, R | 1 |
Andreo, EG; Arcieri, ES; Arcieri, RS; Finotti, IG; Pereira, AC; Sá Filho, WF | 1 |
Alvarado, JA | 1 |
Krupin, T | 1 |
Baker, L; Chuang, AZ; Feldman, RM; Gross, RL; Prager, TC; Reynolds, A; Tanna, AP | 1 |
Georgiadou, I; Kaltsos, K; Katsimpris, IE; Konstas, AG; Kordelou, A; Nelson, LA; Stewart, WC | 1 |
Fuchsjäger-Mayrl, G; Garhofer, G; Resch, H; Schmetterer, L; Weigert, G | 1 |
Barbosa, CP; Biondi, AC; Gerente, VM; Lottenberg, CL; Paranhos, A | 1 |
Hong, S; Kim, CY; Seong, GJ | 1 |
Craven, ER; Katz, LJ; Simmons, ST | 1 |
Akman, A; Akova, YA; Borazan, M; Karalezli, A | 1 |
Esquenazi, S | 1 |
Comez, A; Dogan, OK; Karacan, O; Oral, Y; Ozkurt, Y | 1 |
Anderson, DR; Feuer, W; Schiffman, J | 1 |
Dismuke, WM; Ellis, DZ; Mbadugha, CC | 1 |
Hernández, M; Urcola, JH; Vecino, E | 1 |
Day, DG; Hollander, DA | 1 |
Camras, CB; Gleason, ML; Toris, CB; Yablonski, ME | 1 |
Herrera, AJ; Osborne, NN | 1 |
Debink, N; Gabelt, BT; Hubbard, WC; Kaufman, PL; Peterson, CM; Robinson, JC; Wadhwa, A | 1 |
Chen, KS; Nordlund, JR; Ordman, J; Pasquale, LR; Robin, AL; Rudikoff, MT; Walt, J | 1 |
Chu, TC; Ogidigben, M; Potter, DE | 1 |
Barnebey, HS; Chen, KS; Cinotti, DJ; Coleman, AL; Hersh, SB; Lewis, RA; Morrison, JC; Robin, AL; Walt, J; Zimmerman, TJ | 1 |
Clevenger, CE; David, R; Henry, JC; Passo, MS; Perell, HF; Siegel, LI; Spaeth, GL; Stamper, RL; Stiles, MC; Walt, JG | 1 |
Wilensky, JT | 2 |
Burke, J; Schwartz, M | 1 |
Schuman, JS | 2 |
Walters, TR | 1 |
Serle, JB | 1 |
Arasasingham, PN; Burke, JA; Garst, ME; Harcourt, DA; Kharlamb, AB; Manlapaz, CA; Munk, SA; Padillo, EU; Roberts, D; Runde, E; Wheeler, LA; Williams, L | 1 |
Barnebey, HS; Chen, K; Choplin, N; Derick, RJ; Kelley, EP; Robin, AL; Schuman, J; Stoecker, JF; Walters, TR | 1 |
Hill, R | 1 |
Kohler, C; Markstein, R; Nuttli, I; Prünte, C | 1 |
Albracht, D; Chen, K; Choplin, NT; David, R; Horwitz, B; Schuman, JS | 1 |
Greenfield, DS; Liebmann, JM; Ritch, R | 1 |
Garrison, PM; Stewart, WC | 1 |
Carpineto, P; Ciancaglini, M; Mastropasqua, L | 1 |
LeBlanc, RP | 1 |
Brubaker, RF; Maus, TL; Nau, CB; Schadlu, R | 1 |
Dhanjil, S; Lachkar, Y; Migdal, C | 1 |
Katz, LJ | 2 |
Bogetto, C; Boles Carenini, B; Brogliatti, B; Prandi, B | 1 |
Carpineto, P; Ciancaglini, M; Falconio, G; Gallenga, PE; Mastropasqua, L; Zuppardi, E | 1 |
Boles Carenini, B; Brogliatti, B; Lo Presti, L; Morgese, A; Ravot, M | 1 |
Edward, DP; Lark, KK; Pasha, AS; Yan, X | 1 |
Gebhardt, DO | 1 |
Burnstein, Y; Robin, AL | 2 |
Assalian, A; Chevrier, RL; Duperré, J; Lesk, MR | 1 |
Brubaker, RF; Maus, TL; Nau, C | 1 |
Kaufman, PF | 1 |
Cha, SC; Glover, BK; Kim, C; Kim, YY; Nguyen, KD; Shin, DH | 1 |
Alp, B; Altintaş, O; Cağlar, Y; Karabaş, L; Yüksel, N | 1 |
Buys, YM; thoe Schwartzenberg, GW | 1 |
Barbe, ME; Carlsen, JO; Kwon, YH; Scott, WE; Zabriskie, NA | 1 |
Babighian, S; Bonomi, L; Marchini, G; Tosi, R | 1 |
Camras, CB; Toris, CB; Yablonski, ME | 1 |
Barnes, SD; Campagna, JA; Dirks, MS; Doe, EA | 1 |
Ainsworth, J; Kulshrestha, M; Ng, S; Roff, E; Sedgwick, G | 1 |
Carlsson, AM; Chauhan, BC; Leblanc, RP; Lee, AA | 2 |
Apătăchioae, I; Chiseliţă, D | 1 |
Abrams, C; Gornbein, J; Lee, DA | 1 |
Lee, DA | 1 |
David, R; Melamed, S | 1 |
Fechtner, RD | 1 |
Connor, TB; Dev, S; Han, DP; Mieler, WF; Mittra, RA; Pollack, JS; Pulido, JS | 1 |
Lee, BH; Ma, YR; Park, YG; Yang, KJ | 1 |
Samuelson, TW; Simmons, ST | 1 |
Bucci, MG; Centofanti, M; Cocco, F; Gregori, D; Lorenzano, D; Manni, G | 1 |
Chopra, H; Day, DG; Holmes, KT; Kolker, AE; Konstas, AG; Lee, WH; Rieser, JC; Sharpe, ED; Stewart, WC | 1 |
Javitt, JC; Schiffman, RM | 1 |
Kim, DD | 1 |
Day, DG; Harbin, TS; Holmes, KT; Pastor, SA; Sharpe, ED; Stewart, JA; Stewart, WC | 1 |
Gartaganis, SP; Karamanos, NK; Lamari, F; Mela, EK; Tzovolou, DN | 1 |
Byles, DB; Frith, P; Salmon, JF | 1 |
Goldberg, I; Javitt, J | 1 |
Whitehouse, G | 1 |
Gagliuso, DJ; Podos, SM; Serle, JB; Wang, RF | 1 |
Day, DG; Holmes, KT; Leech, JN; Rowan, CT; Schwartz, GF; Stewart, JA; Stewart, WC | 1 |
Einarson, TR; Iskedjian, M; Kulin, NA; Tingey, D | 1 |
Brogliatti, B; Cipullo, D; Rolle, T; Triggiani, A; Vizzeri, GM | 1 |
Larsson, LI | 1 |
Day, DG; Latham, KE; Schuhr, J; Stewart, JA; Stewart, WC | 1 |
Simmons, ST | 1 |
Chalmers-Redman, RM; Mittag, TW; Podos, SM; Sud, A; Tatton, WG | 1 |
Gil, DW; Wheeler, LA; WoldeMussie, E | 1 |
Ang, RT; Chen, TC; Fan, JT; Grosskreutz, CL; Pasquale, LR | 1 |
Holmes, KT; Konstas, AG; Stangos, NT; Stewart, WC; Tersis, I; Topouzis, F | 1 |
Holmes, KT; Johnson, MA; Stewart, WC | 1 |
Flammer, J; Haefliger, IO; Liu, R | 1 |
Chung, HS; Gazozi, HJ; Harris, A; Ishii, Y; Jonescu-Cuypers, CP; Kagemann, L; Martin, B; Rotenstreich, Y | 1 |
Gornbein, JA; Lee, DA | 1 |
Coulibaly, R | 1 |
Cantor, LB; Flartey, K; Hoop, J; Katz, LJ | 1 |
Findl, O; Georgopoulos, M; Kiss, B; Menapace, R; Petternel, V; Rainer, G | 1 |
Ahmed, FA; Chaudhary, P; Hegazy, K; Sharma, SC | 1 |
Cantatore, F; Cardia, L; Maino, A; Ruggeri, G; Vetrugno, M | 1 |
Enyedi, LB; Freedman, SF | 1 |
Ruiz, G; Wheeler, LA; Wijono, M; WoldeMussie, E | 1 |
Dick, HB; Krummenauer, F; Schwenn, O; Xia, N | 1 |
McKinnon, S; Paris, G; Pena, M; Sanford, K; Sponsel, WE; Trigo, Y; Weber, A | 1 |
Dirks, MS; DuBiner, HB; Mroz, M; Shapiro, AM | 1 |
Earl, ML; Simmons, ST | 1 |
Arias-Puente, A; Kampik, A; O'Brart, DP; Vuori, ML | 1 |
Arici, MK; Erdoğan, H; Sayici, M; Toker, M; Topalkara, A | 1 |
Kasahara, N | 1 |
Chen, YF; Hsiao, CK; Hsieh, JW; Hung, PT; Shein, J | 1 |
Martone, JF; Mead, A; O'Connor, DJ | 1 |
Benozzi, J; Campanelli, JL; Nahum, LP; Rosenstein, RE | 1 |
Mittag, TW; Podos, SM; Serle, JB; Steidl, S; Wang, RF | 1 |
Burke, J; Crosson, C; Potter, D | 1 |
Burke, JA; Potter, DE | 1 |
24 review(s) available for quinoxalines and Intraocular Pressure
Article | Year |
---|---|
Evidence on the neuroprotective properties of brimonidine in glaucoma.
Topics: Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Randomized Controlled Trials as Topic; Vision Disorders; Visual Fields | 2020 |
Brinzolamide plus brimonidine for the treatment of glaucoma: an update.
Topics: Adrenergic alpha-2 Receptor Agonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clinical Trials as Topic; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Sulfonamides; Thiazines | 2014 |
Efficacy, safety, and current applications of brimonidine.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Timolol; Treatment Outcome | 2008 |
[Fixed combinations of glaucoma medications].
Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Cloprostenol; Drug Combinations; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Travoprost; Treatment Outcome | 2008 |
Meta-analysis of medical intervention for normal tension glaucoma.
Topics: Aged; Amides; Antihypertensive Agents; Betaxolol; Bimatoprost; Brimonidine Tartrate; Cloprostenol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Thiazines; Thiophenes; Timolol; Tonometry, Ocular; Travoprost | 2009 |
Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Databases, Factual; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol | 2009 |
Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Patient Selection; Quinoxalines; Risk Assessment; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2010 |
Brimonidine for glaucoma.
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 2010 |
Recent clinical pearls from clinical trials in glaucoma.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Clinical Trials as Topic; Filtering Surgery; Glaucoma Drainage Implants; Humans; Intraocular Pressure; Low Tension Glaucoma; Ocular Hypertension; Quinoxalines; Timolol; Tonometry, Ocular | 2012 |
[The latest developments in glaucoma therapy using fixed combination products].
Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate, Timolol Maleate Drug Combination; Carbonic Anhydrase Inhibitors; Cloprostenol; Drug Combinations; Drug Therapy, Combination; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol; Travoprost; Treatment Outcome | 2011 |
Efficacy and tolerability of fixed combination of brimonidine 0.2%/timolol 0.5% compared with fixed combination of dorzolamide 2%/timolol 0.5% in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Female; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2013 |
[Latanoprost topical ophthalmic combinations].
Topics: Acetazolamide; Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Dinoprost; Drug Combinations; Drug Therapy, Combination; Epinephrine; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Ophthalmic Solutions; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 2004 |
Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Clinical Trials as Topic; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 2007 |
The role of brimonidine in the treatment of open-angle glaucoma.
Topics: Adrenergic alpha-Agonists; Aqueous Humor; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Prostaglandins; Quinoxalines; Sympathomimetics | 1996 |
Preclinical evaluation of brimonidine.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cats; Cebus; Drug Evaluation, Preclinical; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Rabbits; Rats | 1996 |
Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Topics: Acute Disease; Adrenergic alpha-Agonists; Brimonidine Tartrate; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Safety | 1996 |
Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Timolol; Trabeculectomy | 1997 |
Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events.
Topics: Adrenergic beta-Antagonists; Brimonidine Tartrate; Cardiovascular System; Central Nervous System; Clonidine; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Neurosecretory Systems; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Respiratory System; Sulfonamides; Thiophenes | 1998 |
Selectivity of site of action and systemic effects of topical alpha agonists.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Clonidine; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ophthalmic Solutions; Optic Nerve; Quinoxalines; Treatment Outcome | 1998 |
Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aqueous Humor; Brimonidine Tartrate; Clonidine; Drug Synergism; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 1999 |
The role of medical therapy in the rank order of glaucoma treatment.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Laser Therapy; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines; Trabeculectomy; Treatment Outcome | 1999 |
[Alpha-2 adrenergic agonists in the treatment of glaucoma].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Clonidine; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 1999 |
Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma.
Topics: Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines | 2000 |
Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma?
Topics: Animals; Apoptosis; bcl-X Protein; Brimonidine Tartrate; Cell Membrane Permeability; Glaucoma; Humans; Intraocular Pressure; Mitochondria; Pargyline; Propylamines; Proto-Oncogene Proteins c-bcl-2; Quinoxalines; Retinal Ganglion Cells; Signal Transduction | 2001 |
158 trial(s) available for quinoxalines and Intraocular Pressure
Article | Year |
---|---|
Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Prospective Studies; Quinoxalines; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinoxalines; Treatment Outcome | 2023 |
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.
Topics: Adult; Antihypertensive Agents; Brimonidine Tartrate; Endothelial Cells; Glaucoma, Open-Angle; Humans; Hyperemia; Intraocular Pressure; Male; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines | 2023 |
Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%.
Topics: Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Aged; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Double-Blind Method; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiazines; Time Factors; Treatment Outcome | 2013 |
Effect of prophylactic intraocular pressure-lowering medication on pain during cataract surgery.
Topics: Acetazolamide; Adult; Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Cataract; Cloprostenol; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Pain; Phacoemulsification; Postoperative Period; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Travoprost | 2013 |
Effects of dorzolamide-timolol and brimonidine-timolol on retinal vascular autoregulation and ocular perfusion pressure in primary open angle glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Drug Combinations; Eye; Female; Glaucoma, Open-Angle; Homeostasis; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Quinoxalines; Regional Blood Flow; Sulfonamides; Thiophenes; Timolol | 2013 |
Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Cloprostenol; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Quinoxalines; Sulfonamides; Thiophenes; Time Factors; Timolol; Travoprost | 2013 |
Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Topics: Academic Medical Centers; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Aged; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Diagnostic Techniques, Ophthalmological; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Least-Squares Analysis; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Predictive Value of Tests; Private Practice; Quinoxalines; Sulfonamides; Thiazines; Time Factors; Treatment Outcome; United States | 2013 |
Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial.
Topics: Acetazolamide; Administration, Oral; Administration, Topical; Aged; Angiogenesis Inhibitors; Anterior Chamber; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Bevacizumab; Brimonidine Tartrate; Female; Humans; Intraocular Pressure; Intravitreal Injections; Male; Middle Aged; Ocular Hypertension; Paracentesis; Quinoxalines; Tonometry, Ocular | 2014 |
Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiazines; Visual Acuity | 2013 |
Comparison of dorzolamide/timolol versus brimonidine/timolol fixed combination therapy in the management of steroid-induced ocular hypertension.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Diabetic Retinopathy; Drug Combinations; Female; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular; Triamcinolone Acetonide | 2015 |
Evaluation of brimonidine-timolol fixed combination in patients of primary open-angle glaucoma.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Timolol; Treatment Outcome | 2013 |
Risk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study.
Topics: Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Female; Follow-Up Studies; Humans; Intraocular Pressure; Low Tension Glaucoma; Male; Middle Aged; Optic Disk; Proportional Hazards Models; Quinoxalines; Retinal Hemorrhage; Risk Factors; Timolol | 2014 |
Effect of brimonidine on retinal vascular autoregulation and short-term visual function in normal tension glaucoma.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Blood Flow Velocity; Brimonidine Tartrate; Female; Homeostasis; Humans; Intraocular Pressure; Low Tension Glaucoma; Male; Middle Aged; Ophthalmic Solutions; Posture; Prospective Studies; Quinoxalines; Retinal Vessels; Visual Acuity; Visual Field Tests; Visual Fields | 2014 |
Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
Topics: Aged; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Drug Administration Schedule; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ocular Hypotension; Quinoxalines; Tonometry, Ocular; Treatment Outcome | 2013 |
Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Sulfonamides; Thiazines | 2014 |
Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiazines; Tonometry, Ocular; Treatment Outcome | 2014 |
Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Circadian Rhythm; Cloprostenol; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular; Treatment Outcome | 2014 |
Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Treatment Outcome | 2008 |
Changes in visual function after intraocular pressure reduction using antiglaucoma medications.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Cloprostenol; Contrast Sensitivity; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Quinoxalines; Timolol; Travoprost; Visual Acuity; Visual Fields; Visual Perception | 2009 |
An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular; Treatment Outcome; Young Adult | 2008 |
Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Female; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Osmolar Concentration; Quinoxalines; Sulfonamides; Thiophenes; Time Factors; Timolol | 2009 |
Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Cloprostenol; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Single-Blind Method; Sulfonamides; Thiazines; Thiophenes; Tonometry, Ocular; Travoprost; Treatment Outcome | 2009 |
Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Drug Hypersensitivity; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Time Factors; Timolol | 2009 |
Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Drug Combinations; Female; Humans; Injections, Intralesional; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Placebo Effect; Quinoxalines; Ranibizumab; Timolol; Treatment Outcome; Vitreous Body | 2010 |
Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
Topics: Aged; Aged, 80 and over; Algorithms; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Dosage Forms; Double-Blind Method; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Sulfonamides; Thiophenes; Timolol | 2010 |
Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Monitoring; Female; Glaucoma, Open-Angle; Health Behavior; Humans; Intraocular Pressure; Low Tension Glaucoma; Male; Medication Adherence; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Tonometry, Ocular | 2011 |
Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy.
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Capsule Opacification; Cataract; Cloprostenol; Female; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Lasers, Solid-State; Male; Middle Aged; Neodymium; Ocular Hypertension; Ophthalmic Solutions; Posterior Capsule of the Lens; Quinoxalines; Tonometry, Ocular | 2010 |
Effect of prophylactic topical brimonidine (0.15%) administration on the development of subconjunctival hemorrhage after intravitreal injection.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Conjunctival Diseases; Double-Blind Method; Eye Hemorrhage; Female; Humans; Intraocular Pressure; Intravitreal Injections; Male; Middle Aged; Prospective Studies; Quinoxalines | 2011 |
Adherence with brimonidine in patients with glaucoma aware and not aware of electronic monitoring.
Topics: Administration, Topical; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Drug Monitoring; Female; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Medication Adherence; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Patient Compliance; Prospective Studies; Quinoxalines; Visual Acuity | 2011 |
Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Double-Blind Method; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Timolol; Tonometry, Ocular | 2011 |
Effect of a fixed brimonidine-timolol combination on intraocular pressure after phacoemulsification.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Cataract Extraction; Double-Blind Method; Drug Combinations; Female; Humans; Intraocular Pressure; Lens Implantation, Intraocular; Male; Middle Aged; Ocular Hypertension; Phacoemulsification; Prospective Studies; Quinoxalines; Time Factors; Timolol | 2011 |
A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Aged; Brimonidine Tartrate; Double-Blind Method; Female; Follow-Up Studies; Gonioscopy; Humans; Intraocular Pressure; Low Tension Glaucoma; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Timolol; Tonometry, Ocular; Treatment Outcome; Vision Disorders; Visual Acuity; Visual Fields | 2011 |
[Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension].
Topics: Aged; Brimonidine Tartrate, Timolol Maleate Drug Combination; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Male; Middle Aged; Ocular Hypertension; Ophthalmic Artery; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Regional Blood Flow; Retinal Vessels; Timolol; Ultrasonography, Doppler, Color; Vascular Resistance | 2011 |
Effect of brimonidine on corneal thickness.
Topics: Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Cornea; Double-Blind Method; Epithelium, Corneal; Female; Follow-Up Studies; Humans; Intraocular Pressure; Male; Prospective Studies; Quinoxalines; Time Factors; Young Adult | 2011 |
Diurnal intraocular pressure efficacy of the timolol-brimonidine fixed combination and the timolol-dorzolamide fixed combination as a first choice therapy in patients with pseudoexfoliation glaucoma.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Drug Administration Schedule; Drug Combinations; Exfoliation Syndrome; Female; Follow-Up Studies; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Single-Blind Method; Sulfonamides; Thiophenes; Time Factors; Timolol; Treatment Outcome; Visual Acuity | 2011 |
Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucoma.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Medication Adherence; Prospective Studies; Quinoxalines; Sulfonamides; Thiophenes; Time Factors; Timolol; Treatment Outcome | 2012 |
Short-term effects of brimonidine/timolol and dorzolamide/timolol on ocular perfusion pressure and blood flow in glaucoma.
Topics: Administration, Ophthalmic; Aged; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Drug Combinations; Eye; Female; Glaucoma, Open-Angle; Hemodynamics; Humans; Intraocular Pressure; Male; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular | 2012 |
Effects of crystalloid versus colloid and the α-2 agonist brimonidine versus placebo on intraocular pressure during prone spine surgery: a factorial randomized trial.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Brimonidine Tartrate; Chemistry, Pharmaceutical; Colloids; Crystalloid Solutions; Female; Humans; Intraocular Pressure; Intraoperative Care; Isotonic Solutions; Male; Middle Aged; Prone Position; Quinoxalines; Spinal Cord Diseases; Treatment Outcome | 2012 |
Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Time Factors; Timolol; Treatment Outcome | 2012 |
A study of initial therapy for glaucoma in southern India: India Glaucoma Outcomes and Treatment (INGOT) Study.
Topics: Aged; Antihypertensive Agents; Antimetabolites, Antineoplastic; Brimonidine Tartrate; Drug Combinations; Female; Fluorouracil; Glaucoma; Humans; India; Intraocular Pressure; Latanoprost; Lens Implantation, Intraocular; Male; Middle Aged; Phacoemulsification; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Surveys and Questionnaires; Thiophenes; Timolol; Tonometry, Ocular; Trabeculectomy; Visual Acuity | 2012 |
A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
Topics: Aged; Antihypertensive Agents; Blood Flow Velocity; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Drug Combinations; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Time Factors; Timolol; Ultrasonography, Doppler, Color | 2012 |
Fixed combination brimonidine-timolol versus brimonidine for treatment of intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Capsule Opacification; Drug Combinations; Female; Follow-Up Studies; Humans; Intraocular Pressure; Lasers, Solid-State; Male; Middle Aged; Phacoemulsification; Preoperative Care; Quinoxalines; Timolol; Treatment Outcome | 2012 |
[Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections].
Topics: Acetazolamide; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Bevacizumab; Brimonidine Tartrate; Chemoprevention; Clonidine; Drug Combinations; Female; Humans; Hypotonic Solutions; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular; Treatment Outcome | 2012 |
Risk factors for visual field progression in the low-pressure glaucoma treatment study.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Aged; Brimonidine Tartrate; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Gonioscopy; Humans; Intraocular Pressure; Low Tension Glaucoma; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Risk Factors; Timolol; Vision Disorders; Visual Acuity; Visual Field Tests; Visual Fields | 2012 |
[Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combin
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins; Quinoxalines; Timolol; Treatment Outcome | 2012 |
[Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Appetite; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Patient Satisfaction; Quality of Life; Quinoxalines; Surveys and Questionnaires; Treatment Failure; Treatment Outcome | 2002 |
Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma.
Topics: Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Eye; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Pulsatile Flow; Quinoxalines | 2002 |
Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Blood Pressure; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Visual Fields | 2002 |
Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Cross-Over Studies; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular | 2002 |
Effect of single and multiple doses of 0.2% brimonidine tartrate in the glaucomatous Beagle.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glaucoma, Open-Angle; Heart Rate; Intraocular Pressure; Male; Ophthalmic Solutions; Pupil; Quinoxalines; Tonometry, Ocular | 2002 |
Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Cross-Over Studies; Drug Evaluation; Eye; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Optic Disk; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Vision Disorders; Visual Fields | 2002 |
The short-term IOP-lowering effect of brimonidine 0.2% and dorzolomide 2% combination in primary open-angle glaucoma.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Evaluation; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Middle Aged; Ophthalmic Solutions; Quinoxalines; Sulfonamides; Thiophenes | 2002 |
[The ocular hypotensive effect and safety of 0.2% brimonidine].
Topics: Adrenergic alpha-Agonists; Adult; Brimonidine Tartrate; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines | 2001 |
Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Safety; Sulfonamides; Thiophenes; Timolol; Visual Acuity; Visual Fields | 2003 |
A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Conjunctiva; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Double-Blind Method; Glaucoma; Humans; Hyperemia; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Severity of Illness Index | 2003 |
The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Cross-Over Studies; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Posture; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular | 2003 |
Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Chemotherapy, Adjuvant; Dinoprost; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiophenes; Timolol | 2003 |
The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial.
Topics: Blood Flow Velocity; Brimonidine Tartrate; Ciliary Arteries; Eye; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Ophthalmic Artery; Prostaglandins F, Synthetic; Quinoxalines; Retinal Artery; Ultrasonography, Doppler, Color; Vascular Resistance | 2003 |
Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Drug Administration Schedule; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Safety; Timolol | 2003 |
Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes.
Topics: Adrenergic alpha-Agonists; Adult; Brimonidine Tartrate; Exfoliation Syndrome; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Treatment Outcome | 2003 |
Short posterior ciliary artery, central retinal artery, and choroidal hemodynamics in brimonidine-treated primary open-angle glaucoma patients.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Blood Flow Velocity; Brimonidine Tartrate; Choroid; Ciliary Arteries; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Male; Middle Aged; Prospective Studies; Quinoxalines; Retinal Artery; Ultrasonography | 2003 |
Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Analysis of Variance; Brimonidine Tartrate; Contrast Sensitivity; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Middle Aged; Quinoxalines; Receptors, Adrenergic, alpha-2; Timolol | 2003 |
Efficacy of brimonidine 0.2% in controlling acute postoperative intraocular pressure elevation after phacoemulsification.
Topics: Acute Disease; Adrenergic alpha-Agonists; Aged; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Female; Humans; Intraocular Pressure; Lens Implantation, Intraocular; Lenses, Intraocular; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Phacoemulsification; Postoperative Complications; Prospective Studies; Quinoxalines; Treatment Outcome | 2003 |
Aqueous humor flow in normal human eyes treated with brimonidine and dorzolamide, alone and in combination.
Topics: Administration, Topical; Adult; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Cornea; Double-Blind Method; Drug Therapy, Combination; Female; Fluorescein; Fluorophotometry; Humans; Intraocular Pressure; Male; Manometry; Middle Aged; Ophthalmic Solutions; Quinoxalines; Sulfonamides; Thiophenes | 2004 |
Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 2004 |
The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Cross-Over Studies; Dinoprost; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Safety; Treatment Outcome | 2004 |
Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Dinoprost; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Quinoxalines; Timolol; Treatment Outcome | 2005 |
Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Patient Satisfaction; Prospective Studies; Quinoxalines; Safety; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2004 |
Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Cross-Over Studies; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Safety; Sulfonamides; Thiophenes; Treatment Outcome | 2004 |
[Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers].
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quality of Life; Quinoxalines; Sulfonamides; Thiophenes; Tonometry, Ocular; Treatment Outcome | 2004 |
A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Europe; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Timolol; Treatment Outcome | 2004 |
Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Quinoxalines; Sulfonamides; Thiophenes | 2004 |
Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes.
Topics: Adrenergic alpha-Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Dark Adaptation; Female; Humans; Intraocular Pressure; Light; Male; Ophthalmic Solutions; Pupil; Quinoxalines | 2004 |
Effect of topical brinzolamide 1% and brimonidine 0.2% on intraocular pressure after phacoemulsification.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Double-Blind Method; Female; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Phacoemulsification; Postoperative Complications; Prospective Studies; Quinoxalines; Sulfonamides; Thiazines; Tonometry, Ocular | 2004 |
The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.
Topics: Administration, Topical; Adult; Amides; Betaxolol; Bimatoprost; Brimonidine Tartrate; Cardiovascular System; Cloprostenol; Cross-Over Studies; Double-Blind Method; Eye; Humans; Intraocular Pressure; Lipids; Male; Ocular Hypotension; Prospective Studies; Pulmonary Circulation; Quinoxalines; Regional Blood Flow; Travoprost | 2004 |
Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Brimonidine Tartrate; Circadian Rhythm; Drug Administration Schedule; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines | 2004 |
Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.
Topics: Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Quinoxalines; Safety; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2005 |
Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Safety; Tonometry, Ocular; Treatment Outcome; United States | 2005 |
The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Disease Progression; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Quinoxalines; Research Design; Timolol; Visual Field Tests; Visual Fields | 2005 |
[The effect of brimonidine on the pupillary reflex. A pupillographic study in healthy volunteers].
Topics: Acetazolamide; Brimonidine Tartrate; Humans; Intraocular Pressure; Quinoxalines; Reaction Time; Reference Values; Reflex, Pupillary | 2005 |
24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Safety; Sulfonamides; Thiophenes; Visual Acuity | 2005 |
Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Double-Blind Method; Drug Combinations; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Timolol; Treatment Outcome | 2005 |
Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Eye Segment; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Heart Rate; Humans; Intraocular Pressure; Iridectomy; Laser Therapy; Lens Capsule, Crystalline; Male; Ocular Hypertension; Postoperative Complications; Quinoxalines; Trabeculectomy; Treatment Outcome; Visual Acuity | 2005 |
Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study.
Topics: Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Drug Administration Schedule; Female; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Instillation, Drug; Intraocular Pressure; Male; Middle Aged; Nerve Fibers; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Retina; Time Factors; Timolol | 2005 |
Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma.
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Brimonidine Tartrate; Eye; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Instillation, Drug; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome; Ultrasonography, Doppler, Color | 2006 |
A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Cloprostenol; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Quinoxalines; Sulfonamides; Thiazines; Timolol; Travoprost | 2006 |
An evaluation of the rate of nonresponders to latanoprost therapy.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Drug Resistance; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Pilocarpine; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Timolol; Tonometry, Ocular | 2006 |
Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
Topics: Administration, Topical; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Circadian Rhythm; Diastole; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Perfusion; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular | 2006 |
Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy.
Topics: Aged; Brimonidine Tartrate; Double-Blind Method; Female; Humans; Intraocular Pressure; Laser Therapy; Lens Capsule, Crystalline; Male; Middle Aged; Ocular Hypertension; Postoperative Complications; Prospective Studies; Quinoxalines | 2006 |
The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Chlorine Compounds; Double-Blind Method; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Oxides; Polymers; Preservatives, Pharmaceutical; Quinoxalines; Therapeutic Equivalency | 2006 |
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Timolol; Tonometry, Ocular; Treatment Outcome | 2006 |
Visual field and intraocular pressure asymmetry in the low-pressure glaucoma treatment study.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aging; Brimonidine Tartrate; Circadian Rhythm; Double-Blind Method; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Timolol; Visual Fields | 2007 |
Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure.
Topics: Aged; Brimonidine Tartrate; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Instillation, Drug; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiophenes; Timolol | 2007 |
Special considerations in low-tension glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Neuroprotective Agents; Optic Nerve Diseases; Quinoxalines; Retinal Ganglion Cells; Timolol; Vision Disorders; Visual Field Tests; Visual Fields | 2007 |
Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Circadian Rhythm; Cloprostenol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Exfoliation Syndrome; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiazines; Travoprost; Treatment Outcome | 2007 |
Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Time Factors; Timolol; Treatment Outcome | 2008 |
Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Blood Flow Velocity; Brimonidine Tartrate; Choroid; Clonidine; Cross-Over Studies; Double-Blind Method; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Male; Posture; Quinoxalines; Regional Blood Flow; Tonometry, Ocular | 2007 |
Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Dark Adaptation; Diagnostic Techniques, Ophthalmological; Female; Humans; Intraocular Pressure; Male; Miotics; Ophthalmic Solutions; Pupil; Quinoxalines | 2007 |
Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Antihypertensive Agents; Asia; Asian People; Brimonidine Tartrate; Conjunctivitis, Allergic; Cross-Over Studies; Female; Humans; Intraocular Pressure; Male; Ocular Hypertension; Ophthalmic Solutions; Pigment Epithelium of Eye; Preservatives, Pharmaceutical; Prospective Studies; Quinoxalines; Single-Blind Method; Therapeutic Equivalency | 2007 |
Effect of antiglaucoma agents on postoperative intraocular pressure after cataract surgery with Viscoat.
Topics: Acetazolamide; Acetylcholine; Administration, Topical; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Chondroitin; Chondroitin Sulfates; Double-Blind Method; Drug Combinations; Female; Humans; Hyaluronic Acid; Intraocular Pressure; Lens Implantation, Intraocular; Male; Middle Aged; Ocular Hypertension; Phacoemulsification; Postoperative Complications; Prospective Studies; Quinoxalines; Sulfonamides; Thiazines; Timolol; Tonometry, Ocular | 2007 |
Comparison of the effects of dorzolamide-timolol fixed combination and brimonidine on intraocular pressure after phacoemulsification surgery.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Intraocular Pressure; Lens Implantation, Intraocular; Male; Ocular Hypertension; Phacoemulsification; Postoperative Care; Postoperative Complications; Prospective Studies; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2008 |
Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Topics: Adult; Aged; Analysis of Variance; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Maximum Tolerated Dose; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Organization and Administration; Probability; Prostaglandins F, Synthetic; Quinoxalines; Risk Assessment; Severity of Illness Index; Single-Blind Method; Sulfonamides; Thiazines; Tonometry, Ocular; Treatment Outcome | 2008 |
Effects of brimonidine on aqueous humor dynamics in human eyes.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Aged; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Double-Blind Method; Female; Fluorophotometry; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines | 1995 |
The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine.
Topics: Adrenergic alpha-Agonists; Adult; Betaxolol; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Exercise Test; Hemodynamics; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypotension; Ophthalmic Solutions; Quinoxalines; Respiration; Timolol | 1995 |
The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Double-Blind Method; Drug Tolerance; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Pharmaceutical Vehicles; Quinoxalines; Trabeculectomy | 1993 |
Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
Topics: Adrenergic alpha-Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Trabeculectomy | 1993 |
Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Safety; Timolol; Treatment Outcome | 1996 |
A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Safety; Treatment Outcome | 1996 |
Brimonidine tartrate: a one-month dose response study.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glaucoma, Open-Angle; Hemodynamics; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Pupil; Quinoxalines; Visual Acuity | 1997 |
A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glaucoma, Open-Angle; Hemodynamics; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Pupil; Quinoxalines; Safety; Time Factors; Timolol; Treatment Outcome; Visual Acuity | 1997 |
Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Safety; Timolol | 1998 |
Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Topics: Adrenergic alpha-Agonists; Adult; Aqueous Humor; Brimonidine Tartrate; Clonidine; Female; Fluorophotometry; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines; Tonometry, Ocular | 1998 |
Effect of brimonidine tartrate on ocular hemodynamic measurements.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Flow Velocity; Brimonidine Tartrate; Ciliary Arteries; Cross-Over Studies; Double-Blind Method; Eye; Hemodynamics; Humans; Intraocular Pressure; Middle Aged; Ocular Hypertension; Ophthalmic Artery; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Retinal Artery; Ultrasonography, Doppler, Color | 1998 |
Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Safety; Timolol; Treatment Outcome | 1999 |
Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients.
Topics: Adrenergic alpha-Agonists; Aqueous Humor; Blood Pressure; Brimonidine Tartrate; Contrast Sensitivity; Cross-Over Studies; Double-Blind Method; Follow-Up Studies; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ophthalmic Solutions; Pupil; Quinoxalines; Visual Field Tests; Visual Fields | 1998 |
Pressure or progression?
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Disease Progression; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Timolol; Visual Fields | 1999 |
Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrate; Chronic Disease; Clonidine; Female; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Observer Variation; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Trabeculectomy; Treatment Outcome | 1999 |
Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Clonidine; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fluorophotometry; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 1999 |
Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Chronic Disease; Clonidine; Drug Hypersensitivity; Female; Glaucoma, Angle-Closure; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Quinoxalines | 1999 |
The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Brimonidine Tartrate; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Timolol; Treatment Outcome | 1999 |
Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Retrospective Studies; Safety; Treatment Outcome | 1999 |
Effects of 0.2% brimonidine on ocular anterior structures.
Topics: Adrenergic alpha-Agonists; Adult; Brimonidine Tartrate; Eye; Female; Humans; Intraocular Pressure; Male; Prospective Studies; Pupil; Quinoxalines; Ultrasonography; Visual Acuity | 1999 |
Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Aqueous Humor; Brimonidine Tartrate; Double-Blind Method; Female; Fluorophotometry; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Sclera; Time Factors; Venous Pressure | 1999 |
Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Trabeculectomy | 1999 |
The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
Topics: Administration, Topical; Adrenergic alpha-Agonists; Blood Flow Velocity; Brimonidine Tartrate; Disease Progression; Double-Blind Method; Female; Glaucoma; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Retinal Vessels; Visual Fields | 1999 |
The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Brimonidine Tartrate; Cohort Studies; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines | 2000 |
Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quality of Life; Quinoxalines; Racial Groups | 2000 |
Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Female; Glaucoma; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Timolol; Vision Tests | 2000 |
The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Blood Flow Velocity; Brimonidine Tartrate; Double-Blind Method; Female; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Regional Blood Flow; Retinal Vessels; Visual Acuity; Visual Fields | 2000 |
The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation after pars plana vitrectomy with long-acting gas tamponade.
Topics: Administration, Topical; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Clonidine; Fluorocarbons; Humans; Intraocular Pressure; Ocular Hypertension; Prospective Studies; Quinoxalines; Sulfonamides; Sulfur Hexafluoride; Thiophenes; Timolol; Vitrectomy | 2000 |
The efficacy of 0.2% brimonidine for preventing intraocular pressure rise following argon laser trabeculoplasty.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Brimonidine Tartrate; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Safety; Trabeculectomy; Treatment Outcome | 1999 |
Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Miotics; Ocular Hypertension; Pilocarpine; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 2000 |
Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Sulfonamides; Thiophenes; Tonometry, Ocular; Treatment Outcome | 2000 |
Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Topics: Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Safety; Timolol | 2000 |
Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Glaucoma; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quality of Life; Quinoxalines; Safety; Surveys and Questionnaires; Timolol; Treatment Outcome | 2000 |
Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Cross-Over Studies; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Safety; Sulfonamides; Thiophenes; Treatment Outcome | 2000 |
Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Drug Evaluation; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quality of Life; Quinoxalines; Safety; Suspensions; Treatment Outcome | 2000 |
Brimonidine and postoperative pressure spikes in cataract surgery.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Cataract Extraction; Double-Blind Method; Humans; Intraocular Pressure; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Postoperative Complications; Prospective Studies; Quinoxalines; Treatment Outcome | 2000 |
Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Treatment Outcome | 2000 |
Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: brimonidine and latanoprost. Preliminary results.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Blood Flow Velocity; Brimonidine Tartrate; Drug Evaluation; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Retinal Vessels | 2000 |
Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aqueous Humor; Brimonidine Tartrate; Double-Blind Method; Drug Therapy, Combination; Female; Fluorescein; Fluorophotometry; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Timolol; Tonometry, Ocular | 2001 |
The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Safety; Treatment Outcome | 2001 |
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Down-Regulation; Female; Glaucoma; Humans; Immunologic Factors; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quality of Life; Quinoxalines; Sulfonamides; Thiophenes | 2001 |
Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Eye Segment; Blood Pressure; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Iris; Laser Therapy; Male; Ocular Hypertension; Ophthalmic Solutions; Postoperative Complications; Quinoxalines; Safety; Trabeculectomy | 2001 |
Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Brimonidine Tartrate; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Osmolar Concentration; Prospective Studies; Quinoxalines; Timolol | 2001 |
Effect of brimonidine tartrate on ocular hemodynamics in healthy volunteers.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Blood Flow Velocity; Blood Pressure; Brimonidine Tartrate; Ciliary Arteries; Cross-Over Studies; Double-Blind Method; Female; Fluorescein Angiography; Heart Rate; Humans; Intraocular Pressure; Male; Ophthalmic Artery; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Retinal Artery; Tonometry, Ocular; Ultrasonography, Doppler, Color | 2001 |
Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Chemotherapy, Adjuvant; Community Medicine; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Prostaglandins F, Synthetic; Quality of Life; Quinoxalines; Safety | 2001 |
Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Female; Humans; Intraocular Pressure; Male; Middle Aged; Multicenter Studies as Topic; Ocular Hypertension; Quality of Life; Quinoxalines; Treatment Outcome | 2001 |
Effect of topical brimonidine on intraocular pressure after small incision cataract surgery.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Double-Blind Method; Female; Humans; Intraocular Pressure; Lens Implantation, Intraocular; Male; Minimally Invasive Surgical Procedures; Ocular Hypertension; Phacoemulsification; Postoperative Complications; Prospective Studies; Quinoxalines | 2001 |
Safety and efficacy of brimonidine in children with glaucoma.
Topics: Adolescent; Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Central Nervous System Diseases; Child; Child, Preschool; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines; Safety; Tonometry, Ocular | 2001 |
[Prevention of early postoperative increase in intraocular pressure after phacoemulsification. Comparison of different antiglaucoma drugs].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Data Interpretation, Statistical; Double-Blind Method; Drug Therapy, Combination; Humans; Intraocular Pressure; Lens Implantation, Intraocular; Middle Aged; Ophthalmic Solutions; Phacoemulsification; Polysaccharides, Bacterial; Postoperative Care; Postoperative Complications; Quinoxalines; Sulfonamides; Thiophenes; Time Factors; Timolol | 2001 |
Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Flow Velocity; Brimonidine Tartrate; Contrast Sensitivity; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Indomethacin; Intraocular Pressure; Laser-Doppler Flowmetry; Latanoprost; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Retinal Vessels; Visual Fields | 2002 |
A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
Topics: Adrenergic alpha-Agonists; Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Patient Satisfaction; Prostaglandins F, Synthetic; Quinoxalines; Treatment Outcome | 2001 |
Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Brimonidine Tartrate; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Prostaglandins F, Synthetic; Quality of Life; Quinoxalines; Treatment Outcome | 2002 |
Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Treatment Outcome | 2002 |
Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Double-Blind Method; Drug Evaluation; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Patient Satisfaction; Preservatives, Pharmaceutical; Quality of Life; Quinoxalines; Safety | 2002 |
A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Quinoxalines; Timolol | 2002 |
106 other study(ies) available for quinoxalines and Intraocular Pressure
Article | Year |
---|---|
Can bleeding in trabeculectomy be decreased? Effectiveness of brimonidine pre-treatment.
Topics: Brimonidine Tartrate; Conjunctival Diseases; Eye Hemorrhage; Humans; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines; Trabeculectomy | 2022 |
Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Sulfonamides; Thiazines | 2022 |
Comments on
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Delivery Systems; Eye; Haplorhini; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines | 2022 |
Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Intraocular Pressure; Liposomes; Polymers; Quinoxalines; Rabbits; Timolol | 2023 |
[Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 2019 |
[Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines | 2019 |
Brimonidine allergy presenting as vernal-like keratoconjunctivitis.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Diagnosis, Differential; Drug Hypersensitivity; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Quinoxalines; Withholding Treatment | 2015 |
Suspected granulomatous anterior uveitis associated with brimonidine tartrate 0.2% and timolol maleate 0.5% ophthalmic solution.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Female; Glaucoma, Open-Angle; Granuloma; Humans; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines; Timolol; Uveitis, Anterior | 2013 |
Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Dogs; Female; Forecasting; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Models, Biological; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Rabbits; Translational Research, Biomedical; Treatment Outcome | 2014 |
28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Delivery Systems; Intraocular Pressure; Microspheres; Models, Animal; Quinoxalines; Rabbits | 2014 |
Anterior and posterior segment changes in rat eyes with chronic steroid administration and their responsiveness to antiglaucoma drugs.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Catalase; Dexamethasone; Disease Models, Animal; Female; Glutathione; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Oxidative Stress; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Rats, Sprague-Dawley; Retina; Sulfonamides; Superoxide Dismutase; Thiophenes; Timolol | 2015 |
Totally one-sided: painless unilateral proptosis.
Topics: Aged, 80 and over; Antihypertensive Agents; Arteriovenous Fistula; Brimonidine Tartrate; Carotid Artery, Internal; Cavernous Sinus; Cerebral Angiography; Diagnosis, Differential; Exophthalmos; Female; Humans; Intraocular Pressure; Levobunolol; Ophthalmic Solutions; Quinoxalines; Sulfonamides; Thiophenes; Tomography, X-Ray Computed; Treatment Outcome; Vision Disorders | 2015 |
Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Aqueous Humor; Blotting, Western; Brimonidine Tartrate; Cell Membrane Permeability; Cells, Cultured; Dinucleoside Phosphates; Drug Delivery Systems; Electric Impedance; Epithelium, Corneal; Glaucoma; Humans; Intraocular Pressure; Male; Occludin; Quinoxalines; Rabbits; Tight Junctions; Timolol; Zonula Occludens-1 Protein | 2015 |
Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Drug Therapy, Combination; Female; Germany; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Timolol; Visual Fields; Young Adult | 2009 |
Temporal evolution of intraocular pressure elevation after pupillary dilation in pigment dispersion syndrome.
Topics: Adult; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Exfoliation Syndrome; Humans; Intraocular Pressure; Male; Middle Aged; Mydriatics; Ocular Hypertension; Phenylephrine; Pupil; Quinoxalines; Retrospective Studies; Tonometry, Ocular; Tropicamide | 2009 |
A medical device/drug delivery system for treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Contact Lenses; Drug Delivery Systems; Female; Glaucoma; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Timolol | 2009 |
Matrix metalloproteinase-9 expression in retinal ganglion cell layer and effect of topically applied brimonidine tartrate 0.2% therapy on this expression in an endothelin-1-induced optic nerve ischemia model.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Gene Expression Regulation, Enzymologic; In Situ Nick-End Labeling; Infusion Pumps; Intraocular Pressure; Matrix Metalloproteinase 9; Optic Neuropathy, Ischemic; Quinoxalines; Rabbits; Retinal Ganglion Cells | 2010 |
Aerobic exercise and intraocular pressure in normotensive and glaucoma patients.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Exercise; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 2009 |
Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation.
Topics: Acetylcysteine; Animals; Brimonidine Tartrate; Catalase; Disease Models, Animal; Drug Therapy, Combination; Glutathione Peroxidase; Hyaluronic Acid; Intraocular Pressure; Male; Malondialdehyde; Nitric Oxide; Ocular Hypertension; Oxidative Stress; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Diseases; Tonometry, Ocular | 2009 |
Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Glial Fibrillary Acidic Protein; Gliosis; Intraocular Pressure; Latanoprost; Male; Neuroglia; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Retina; Timolol; Tonometry, Ocular | 2010 |
Short-term effect of topical brimonidine tartrate on intrastromal corneal pressure in rabbits.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Animals; Antihypertensive Agents; Brimonidine Tartrate; Corneal Stroma; Intraocular Pressure; Male; Quinoxalines; Rabbits; Tonometry, Ocular | 2010 |
Brimonidine and eye pressure.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Humans; Intraocular Pressure; Low Tension Glaucoma; Quinoxalines | 2010 |
Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Eye; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Treatment Outcome | 2010 |
Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure.
Topics: Adrenergic alpha-Agonists; Aged; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Circadian Rhythm; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Quinoxalines | 2010 |
Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion.
Topics: Animals; Antihypertensive Agents; Aqueous Humor; Betaxolol; Brimonidine Tartrate; Coloring Agents; Dextrans; Fluorescein-5-isothiocyanate; Intraocular Pressure; Latanoprost; Male; Manometry; Mice; Mice, Inbred BALB C; Prostaglandins F, Synthetic; Quinoxalines; Sclera; Tonometry, Ocular; Trabecular Meshwork; Uvea; Venous Pressure | 2011 |
Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Low Tension Glaucoma; Male; Middle Aged; Prospective Studies; Pupil; Quinoxalines; Timolol; Tonometry, Ocular; Treatment Outcome | 2010 |
The clinical impact of 2 different strategies for initiating therapy in patients with ocular hypertension.
Topics: Adult; Antihypertensive Agents; Blindness; Brimonidine Tartrate; Decision Trees; Disease Progression; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Markov Chains; Middle Aged; Models, Biological; Monte Carlo Method; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Risk Assessment; Sulfonamides; Thiophenes; Timolol | 2011 |
Prevention of retinal ganglion cell swelling by systemic brimonidine in a rat experimental glaucoma model.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glaucoma, Open-Angle; Injections, Intraperitoneal; Intraocular Pressure; Papilledema; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Treatment Outcome | 2011 |
Asymmetry of 24-hour intraocular pressure reduction by topical ocular hypotensive medications in fellow eyes.
Topics: Administration, Topical; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Cloprostenol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Posture; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Sulfonamides; Thiazines; Timolol; Tonometry, Ocular; Travoprost | 2011 |
Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration.
Topics: Adult; Anterior Eye Segment; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Female; Glaucoma, Open-Angle; Gonioscopy; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Pilocarpine; Pupil; Quinoxalines; Timolol; Tonometry, Ocular | 2011 |
Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
Topics: Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Glaucoma; Hydrogen-Ion Concentration; Intraocular Pressure; Kinetics; Nanoparticles; Nanotechnology; Quinoxalines; Rabbits; Solubility; Technology, Pharmaceutical | 2011 |
Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Calorimetry, Differential Scanning; Chitosan; Delayed-Action Preparations; Drug Compounding; Drug Delivery Systems; Electrochemistry; Excipients; Eye; Freeze Drying; Intraocular Pressure; Irritants; Membranes; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Ophthalmic Solutions; Particle Size; Quinoxalines; Rabbits; Solubility; Spectroscopy, Fourier Transform Infrared | 2011 |
Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
Topics: Absorbable Implants; Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Alginates; Animals; Brimonidine Tartrate; Calorimetry, Differential Scanning; Cellulose; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Compounding; Glaucoma; Glucuronic Acid; Hexuronic Acids; Hydrophobic and Hydrophilic Interactions; Hypromellose Derivatives; Intraocular Pressure; Kinetics; Methylcellulose; Ophthalmic Solutions; Polymers; Polymethacrylic Acids; Polyvinyls; Povidone; Quinoxalines; Rabbits; Solubility; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; X-Ray Diffraction | 2011 |
[Effect of brimonidine on central corneal thickness].
Topics: Adrenergic alpha-2 Receptor Agonists; Antihypertensive Agents; Brimonidine Tartrate; Cornea; Female; Humans; Intraocular Pressure; Male; Organ Size; Quinoxalines; Young Adult | 2012 |
The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma.
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Drug Costs; Economics, Pharmaceutical; Follow-Up Studies; Glaucoma, Open-Angle; Health Care Costs; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quality-Adjusted Life Years; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2012 |
Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for glaucoma.
Topics: Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Feasibility Studies; Intraocular Pressure; Latanoprost; Mice; Mice, Inbred C57BL; Microspheres; Muscarinic Agonists; Ocular Hypertension; Optic Nerve; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Retinal Ganglion Cells; Sulfonamides; Thiazines; Timolol; Tomography, Optical Coherence | 2012 |
Comparison of the progression rates of the superior, inferior, and both hemifield defects in normal-tension glaucoma patients.
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Cohort Studies; Disease Progression; Female; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Nerve Fibers; Prostaglandins F, Synthetic; Quinoxalines; Retinal Ganglion Cells; Retrospective Studies; Tonometry, Ocular; Vision Disorders; Visual Field Tests; Visual Fields | 2012 |
The activity of lowering intraocular pressure of cassiae seed extract in a DBA/2J mouse glaucoma model.
Topics: Acetazolamide; Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Cassia; Chromatography, High Pressure Liquid; Disease Models, Animal; Glaucoma; Glycosides; Intraocular Pressure; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred DBA; Plant Extracts; Polyphenols; Quinoxalines; Seeds | 2013 |
[Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Clinical Trials as Topic; Glaucoma; Humans; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines | 2012 |
[Use of glaucoma medications during pregnancy and breastfeeding].
Topics: Abnormalities, Drug-Induced; Administration, Ophthalmic; Administration, Oral; Adrenergic beta-Antagonists; Animals; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Contraindications; Female; Fetus; Gels; Glaucoma; Humans; Hypotension; Intraocular Pressure; Lactation; Obstetric Labor, Premature; Ophthalmic Solutions; Pregnancy; Pregnancy Complications; Prostaglandins; Quinoxalines; Timolol | 2012 |
Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma.
Topics: Administration, Topical; Aged; Antihypertensive Agents; Betaxolol; Blood Flow Velocity; Brimonidine Tartrate; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Ophthalmic Solutions; Prostaglandins F, Synthetic; Pulsatile Flow; Quinoxalines; Retrospective Studies; Tonometry, Ocular; Trabeculectomy | 2002 |
Effect of brimonidine on patients undergoing uncontrolled IOP with beta-blockers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Chronic Disease; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Quinoxalines; Treatment Failure | 2002 |
A paradoxical ocular effect of brimonidine.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines | 2003 |
Brimonidine and latanoprost as adjunctive therapy.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Chemotherapy, Adjuvant; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Prostaglandins F, Synthetic; Quality of Life; Quinoxalines; Randomized Controlled Trials as Topic | 2003 |
Evaluation of the intraocular pressure-reducing effect of latanoprost as monotherapy in open-angle glaucoma.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Middle Aged; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 2002 |
Incubation of porcine iris-ciliary bodies to study the mechanisms by which nitric oxide donors lower intraocular pressure.
Topics: Animals; Captopril; Ciliary Body; Cyclic GMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanylate Cyclase; Intraocular Pressure; Iris; Nitrates; Nitric Oxide; Nitric Oxide Donors; Nitrites; Nitro Compounds; Nitrogen Oxides; Oxadiazoles; Penicillamine; Phosphodiesterase Inhibitors; Purinones; Quinoxalines; Rabbits; S-Nitrosothiols; Spermine; Swine; Time Factors | 2003 |
Miotic effect of alphagan P.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Female; Glaucoma, Angle-Closure; Humans; Intraocular Pressure; Iris Diseases; Pupil; Quinoxalines | 2003 |
Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Bradycardia; Brimonidine Tartrate; Female; Glaucoma; Humans; Hypotension; Infant; Infant, Newborn; Intraocular Pressure; Quinoxalines | 2003 |
Patient persistency with pharmacotherapy in the management of glaucoma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Cohort Studies; Drug Utilization; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Middle Aged; Ocular Hypertension; Patient Compliance; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes | 2003 |
Bilateral simultaneous anterior ischemic optic neuropathy in a young, healthy man.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Brimonidine Tartrate; Drug Therapy, Combination; Humans; Intraocular Pressure; Male; Optic Neuropathy, Ischemic; Quinoxalines; Visual Acuity; Visual Field Tests; Visual Fields | 2003 |
Brimonidine and latanoprost as adjunctive therapy.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 2004 |
Tonopen measurement of intraocular pressure in mice.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Catheterization; Intraocular Pressure; Manometry; Mice; Mice, Inbred C57BL; Models, Animal; Quinoxalines; Rats; Rats, Inbred BN; Reproducibility of Results | 2004 |
Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Female; Glaucoma; Glucocorticoids; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Prednisolone; Quinoxalines; Uveitis, Anterior | 2004 |
Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Female; Filtering Surgery; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Outpatient Clinics, Hospital; Patient Acceptance of Health Care; Prospective Studies; Quinoxalines; Time Factors | 2005 |
[Neuroprotection and vasoprotection in glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Carteolol; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Neuroprotective Agents; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 2004 |
Intravitreal triamcinolone injection for diabetic macular edema: a clinical and fluorescein angiographic case series.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Diabetic Retinopathy; Female; Fluorescein Angiography; Glucocorticoids; Humans; Injections; Intraocular Pressure; Laser Coagulation; Macular Edema; Male; Middle Aged; Pilot Projects; Quinoxalines; Retrospective Studies; Triamcinolone Acetonide; Visual Acuity; Vitreous Body | 2004 |
Bilateral retinal venous occlusion in pigmentary glaucoma.
Topics: Adult; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Exfoliation Syndrome; Functional Laterality; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Quinoxalines; Retinal Vein Occlusion; Timolol; Trabecular Meshwork; Vision Disorders; Visual Field Tests; Visual Fields | 2005 |
Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Aqueous Humor; Blood Pressure; Brimonidine Tartrate; Ciliary Body; Cornea; Heart Rate; Intraocular Pressure; Laser-Doppler Flowmetry; Oxygen; Quinoxalines; Rabbits; Regional Blood Flow; Vasoconstrictor Agents | 2006 |
Side-effect profile of brimonidine tartrate in children.
Topics: Adolescent; Adrenergic alpha-Agonists; Brimonidine Tartrate; Central Nervous System Diseases; Child; Child, Preschool; Female; Glaucoma; Humans; Infant; Intraocular Pressure; Male; Prospective Studies; Quinoxalines; Risk Factors; Sleep; Sleep Stages; Surveys and Questionnaires | 2005 |
Argon laser trabeculoplasty and reduction of ocular hypotensive medication used by glaucoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Chronic Disease; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Quinoxalines; Trabeculectomy; Treatment Outcome | 2006 |
[Ocular hypertension in children treated with brimonidine 0.2%. A clinical study].
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Child; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ocular Hypertension; Quinoxalines; Retrospective Studies; Treatment Outcome | 2006 |
A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy.
Topics: Acute Disease; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Dizocilpine Maleate; Glatiramer Acetate; Immunization; Injections; Intraocular Pressure; Male; Neuroprotective Agents; Ocular Hypertension; Optic Nerve Diseases; Peptides; Quinoxalines; Rats; Rats, Inbred Lew; Retinal Ganglion Cells; Vaccination | 2006 |
[Intraocular pressure after ND: YAG laser capsulotomy in pseudophakic patients with glaucoma].
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Cataract Extraction; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Lens Capsule, Crystalline; Preoperative Care; Pseudophakia; Quinoxalines; Sulfonamides; Thiophenes | 2006 |
Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs.
Topics: Administration, Topical; Aged; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Carteolol; Case-Control Studies; Chemokines; Cloprostenol; Cytokines; Dose-Response Relationship, Immunologic; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Lipids; Male; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Tears; Thiophenes; Timolol | 2007 |
Brimonidine/Timolol: a viewpoint by Richard Fiscella.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Randomized Controlled Trials as Topic; Timolol; Treatment Outcome | 2006 |
Brimonidine/Timolol: a viewpoint by Francisco J. Goñi.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2006 |
Reduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timolol.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Clinical Trials as Topic; Conjunctivitis, Allergic; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Timolol | 2007 |
Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Brimonidine Tartrate; Cloprostenol; Female; Humans; Instillation, Drug; Intraocular Pressure; Latanoprost; Macular Edema; Prednisolone; Prostaglandins F, Synthetic; Pseudophakia; Quinoxalines; Tomography, Optical Coherence; Travoprost; Treatment Outcome | 2007 |
Normal-tension glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aging; Brimonidine Tartrate; Circadian Rhythm; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Quinoxalines; Timolol; Visual Fields | 2008 |
New drug information. Combigan.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Timolol | 2008 |
NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel.
Topics: Adult; Aged; Aged, 80 and over; Animals; Aqueous Humor; Cell Line; Cell Size; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Guanylate Cyclase; Humans; Intraocular Pressure; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Microscopy, Confocal; Middle Aged; Nitric Oxide; Nitric Oxide Donors; Osmolar Concentration; Oxadiazoles; Peptides; Perfusion; Potassium Channel Blockers; Quinoxalines; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Swine; Thionucleotides; Time Factors; Tissue Culture Techniques; Trabecular Meshwork | 2008 |
Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Intraocular Pressure; Latanoprost; Neuroprotective Agents; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells | 2008 |
The effect of experimental ischaemia and excitatory amino acid agonists on the GABA and serotonin immunoreactivities in the rabbit retina.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Aminobutyrates; Animals; Cycloleucine; Dextromethorphan; Eye Proteins; gamma-Aminobutyric Acid; Glucose; Glutamates; Glutamic Acid; Intraocular Pressure; Ischemia; Kainic Acid; Kynurenic Acid; Memantine; N-Methylaspartate; Oxygen; Potassium Cyanide; Quinoxalines; Rabbits; Receptors, AMPA; Receptors, Glutamate; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Retina; Retinal Vessels; Serotonin | 1994 |
Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys.
Topics: Adrenergic alpha-Agonists; Animals; Aqueous Humor; Blood Pressure; Body Weight; Brimonidine Tartrate; Clonidine; Dose-Response Relationship, Drug; Female; Heart Rate; Intraocular Pressure; Macaca fascicularis; Macaca mulatta; Male; Pupil; Quinoxalines; Refraction, Ocular; Sympathectomy | 1994 |
Alpha-2 adrenoceptor mediated changes in aqueous dynamics: effect of pertussis toxin.
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Cyclic AMP; Intraocular Pressure; Kinetics; Norepinephrine; Pertussis Toxin; Quinoxalines; Rabbits; Uvea; Virulence Factors, Bordetella | 1994 |
Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blood-Brain Barrier; Brimonidine Tartrate; Imidazoles; Intraocular Pressure; Macaca fascicularis; Quinoxalines; Rabbits | 1997 |
New agents for the treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines | 1997 |
Brimonidine--an alpha 2-agonist for glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Clinical Trials as Topic; Contraindications; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Xerostomia | 1997 |
Effects of dopamine D-1 and D-2 receptors on intraocular pressure in conscious rabbits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Aqueous Humor; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Fluorophotometry; Intraocular Pressure; Pupil; Quinolines; Quinoxalines; Rabbits; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1997 |
Brimonidine and pupillary diameter.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Dose-Response Relationship, Drug; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Pupil; Quinoxalines; Safety | 1998 |
Pupillographic, tonographic and refractive parameter changes after topical instillation of Brimonidine tartrate 0.2% in healthy subjects.
Topics: Accommodation, Ocular; Administration, Topical; Adrenergic alpha-Agonists; Adult; Aqueous Humor; Brimonidine Tartrate; Female; Follow-Up Studies; Humans; Intraocular Pressure; Male; Pupil; Quinoxalines; Reference Values; Refraction, Ocular; Tonometry, Ocular | 1998 |
Ultrabiomicroscopic study of the effects of brimonidine, apraclonidine, latanoprost and ibopamine on the chamber angle and ciliary body.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Chamber; Brimonidine Tartrate; Ciliary Body; Clonidine; Deoxyepinephrine; Female; Follow-Up Studies; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Mydriatics; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Reference Values; Ultrasonography | 1998 |
The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Division; Conjunctiva; Disease Models, Animal; Fibroblasts; Glaucoma; Intraocular Pressure; Latanoprost; Microfilament Proteins; Ophthalmic Solutions; Proliferating Cell Nuclear Antigen; Prostaglandins F, Synthetic; Quinoxalines; Rabbits | 1999 |
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Approval; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Netherlands; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1999 |
Apparent central nervous system depression in infants after the use of topical brimonidine.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Central Nervous System; Follow-Up Studies; Glaucoma; Humans; Infant; Infant, Newborn; Intraocular Pressure; Male; Nervous System Diseases; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines | 1999 |
Demonstration of the reversibility of optic disc topography by scanning laser ophthalmoscopy.
Topics: Adrenergic alpha-Agonists; Aniridia; Brimonidine Tartrate; Child; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Lasers; Latanoprost; Male; Ophthalmoscopy; Optic Disk; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Trabeculectomy; Visual Acuity | 1999 |
Initial medical management of open-angle glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Hypertension; Intraocular Pressure; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Quinoxalines | 2000 |
Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Safety; Sulfonamides; Thiophenes; Tonometry, Ocular | 2000 |
A case of suspected alphagan-induced psychosis.
Topics: Acute Disease; Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Delirium; Glaucoma, Open-Angle; Hallucinations; Humans; Intraocular Pressure; Male; Psychoses, Substance-Induced; Quinoxalines; Visual Acuity | 2000 |
Capillary electrophoretic analysis of brimonidine in aqueous humor of the eye and blood sera and relation of its levels with intraocular pressure.
Topics: Adrenergic alpha-Agonists; Aged; Aqueous Humor; Brimonidine Tartrate; Calibration; Electrophoresis, Capillary; Female; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines | 2000 |
Anterior uveitis as a side effect of topical brimonidine.
Topics: Acute Disease; Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrate; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines; Recurrence; Uveitis, Anterior; Visual Acuity | 2000 |
Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Synergism; Drug Therapy, Combination; Female; Glaucoma; Intraocular Pressure; Latanoprost; Macaca fascicularis; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Random Allocation; Sulfonamides; Thiophenes; Timolol | 2000 |
Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Immunoenzyme Techniques; Intraocular Pressure; Neuroprotective Agents; Ocular Hypertension; Optic Nerve Injuries; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Retina; Retinal Ganglion Cells; Signal Transduction | 2001 |
Washout periods for brimonidine 0.2% and latanoprost 0.005%.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Single-Blind Method; Time Factors | 2001 |
Brimonidine and inhibition of nitrite production in isolated porcine ciliary processes.
Topics: Adrenergic alpha-Agonists; Animals; Aqueous Humor; Brimonidine Tartrate; Ciliary Body; Colforsin; Intraocular Pressure; Nitric Oxide; Nitrites; Quinoxalines; Swine | 2001 |
Systemic beta-blocker therapy and brimonidine and timolol.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Clinical Trials as Topic; Glaucoma, Open-Angle; Hemodynamics; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Safety; Timolol | 2001 |
Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure.
Topics: Adrenergic alpha-Antagonists; Age Factors; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Disease Models, Animal; Female; Glaucoma; Intraocular Pressure; Nerve Degeneration; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Retinal Ganglion Cells; Time Factors | 2001 |
Acute and chronic effects of brimonidine 0.2% on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Drug Administration Schedule; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Pulsatile Flow; Quinoxalines; Time Factors | 2001 |
Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Brimonidine Tartrate; Cell Survival; Chronic Disease; Cytoprotection; Glial Fibrillary Acidic Protein; Intraocular Pressure; Laser Coagulation; Male; Neuroprotective Agents; Ocular Hypertension; Quinoxalines; Rats; Rats, Wistar; Retina; Retinal Ganglion Cells; Time Factors; Timolol | 2001 |
Brimonidine 0.2% to prevent post laser IOP elevation.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Iris; Laser Therapy; Ocular Hypertension; Postoperative Complications; Quinoxalines; Trabeculectomy | 2002 |
The efficacy of brimonidine in preventing intraocular pressure elevation in the provocative test for primary angle-closure glaucoma.
Topics: Adult; Aged; Brimonidine Tartrate; Darkness; Female; Glaucoma, Angle-Closure; Humans; Intraocular Pressure; Male; Middle Aged; Posture; Prone Position; Quinoxalines | 2002 |
Additive intraocular pressure lowering effect of various medications with latanoprost.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Synergism; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes | 2002 |
Effect of hyaluronic acid on intraocular pressure in rats.
Topics: Animals; Anterior Chamber; Antihypertensive Agents; Brimonidine Tartrate; Disease Models, Animal; Hyaluronic Acid; Injections; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Timolol; Tonometry, Ocular | 2002 |
Selective alpha 2-adrenergic agonists B-HT 920 and UK14304-18. Effects on aqueous humor dynamics in monkeys.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Aqueous Humor; Azepines; Brimonidine Tartrate; Intraocular Pressure; Macaca fascicularis; Quinoxalines; Time Factors; Tonometry, Ocular | 1991 |
Can UK-14, 304-18 lower IOP in rabbits by a peripheral mechanism?
Topics: Administration, Topical; Animals; Anterior Chamber; Blood Pressure; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Routes; Female; Ganglia, Sympathetic; Ganglionectomy; Heart Rate; Injections; Intraocular Pressure; Male; Pupil; Quinoxalines; Rabbits | 1989 |
Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cats; Cebus; Eye; Female; Intraocular Pressure; Male; Neurons; Ocular Hypertension; Pupil; Quinoxalines; Rabbits; Water | 1986 |